 "Suven Life Sciences surges on bagging three product patents")
Suven Life Sciences climbs 5% on receiving one product patent each from New Zealand, Singapore and USA corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2032.
After receiving these new patents, the company has now a total of 24 granted patents from New Zealand, 22 granted product patents from Singapore and 22 granted patents from USA. These granted patents are exclusive intellectual property of Suven and are attained via the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Venkat Jasti, CEO of Suven stated that Suven is very pleased by the grant of these patents for the pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.
The stock opened at Rs 270 and touched a high of Rs 283 on the BSE . A total of 496,700 shares changed hands on the BSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%